Thus, SAMHD1 may primarily be a biomarker for doxorubicin resistance in impacting clinical outcomes for DLBCL patients treated with R-CHOP although our model does not rule out the possibility that SAMHD1 may also mediate resistance to other R-CHOP agents that could indirectly induce DSBs. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.